Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Brakes Put On Brandname Pharmaceuticals

Sales Set for Substantial Slowdown

    This is a preview of subscription content, log in to check access.

    Table I
    Table II
    Table III
    Table IV

    References

    1. 1.

      PharmaPipelines: strategic analysis and conclusions 2006. Lehman Brothers, 2006 Sep 15

    2. 2.

      Incretin-targeting technologies for type 2 diabetes: dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 analogs. Pharma ceutical & Diagnostic Innovation 2006; 4 (7): 3–7

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Brakes Put On Brandname Pharmaceuticals. Pharmaceutical & Diagnostic Innovation 4, 7–10 (2006). https://doi.org/10.1007/BF03257110

    Download citation

    Keywords

    • Exenatide
    • Sitagliptin
    • Cetirizine
    • Abatacept
    • Vildagliptin